Samsung Enabling Open Innovation Culture Among Employees Globally Through its C-Lab Program

Samsung-Enabling-Open-Innov

Smartphone and consumer electronics major Samsung is promoting a strong culture of innovation among its employees globally, including in India, through its C-Lab (Creative Lab) program. C-Lab is an in-house ideas incubation program that enables employees to develop their creative ideas into meaningful offerings while staying within the company.

C-Lab aims to cultivate a creative culture at Samsung that inspires employees to freely propose innovative ideas and solutions that respond to the world’s challenges. Employees whose ideas get selected through C-Lab program work as a startup within Samsung for one year, separately from the normal work environment. C-Lab members have the flexibility to decide their own working hours and days. They can also set their own rules and hire additional members.

Twice every year, employees can pitch their ideas through an internal system that go through online voting and are reviewed by experts. The final idea pitches happen in front of 100 employees, an evaluation group and 10 executives of Samsung.

“Our vision for C-Lab is to expand the creative culture within the company by discovering and implementing innovative ideas. We are striving towards hybrid innovation, which combines the know-how of a large corporation and the spirit of the challenge of a small venture company to spread everywhere in Samsung,” said Mark Sohn of the Creativity and Innovation Center, Samsung Electronics.

The selected teams work on prototyping their ideas and market testing them in the one-year time when they work with Samsung as a startup. These teams get multiple opportunities to show their progress and receive feedback. One opportunity is the C-Lab fair held every November. Another is an opportunity to get feedback from external customers by showcasing prototypes at global exhibitions such as CES, MWC and South by Southwest.

Starting 2015, Samsung introduced the spin-off program for C-Lab projects. Those projects that were not closely related to Samsung’s business and had not been transferred to an in-house division, were spun-off.

An example of the success of the C-Lab program is a company founded by Pankaj Agarwal, who joined Samsung in South Korea in 2004. Today, his startup TagHive, a C-Lab spin-off, offers AI-powered smart school solutions to connect students, teachers and parents for a better feedback loop for all. TagHive’s ‘Class Saathi’, a clicker-based classroom response system, is helping reduce student dropouts in Indian government schools. TagHive is currently working closely with Uttar Pradesh, Madhya Pradesh and Odisha state governments to deploy Class Saathi.

In the last 10 years since C-Lab started, over 1,507 employees have participated in 365 C-Lab projects globally. Many innovations have sprung from C-Lab over the years that are now part of Samsung – like Galaxy Upcycling, Eco-packaging, Lifestyle TV ‘The Sero’, and new features for mobile cameras and Samsung Pay. The program has enabled 59 startups.

In 2018, Samsung also introduced the C-Lab Outside program to vitalize the startup ecosystem and promote job creation, helping startups to grow their business through financial aid, mentoring, consultation, business cooperation and infrastructural support.

Maruti Suzuki sales in July 2022

Maruti Suzuki sales in July 2022

Maruti Suzuki India Limited clocked total sales of 175,916 units in July 2022. Total sales in the month include domestic sales of 145,666 units, sales to other OEM of 9,939 units and exports of 20,311 units.

The shortage of electronic components had a minor impact on the production of vehicles, mainly in domestic models. The Company took all possible measures to minimise the impact.

The sales figures for July 2022 are given below:

Maruti Suzuki sales in July 2022
 Category: Sub-segment ModelsJulyApril-July
202220212022-232021-22
A: MiniAlto, S-Presso20,33319,68569,32066,925
A: CompactBaleno, Celerio, Dzire, Ignis, Swift, Tour S, WagonR84,81870,268289,695231,778
Mini + Compact Segment105,15189,953359,015298,703
A: Mid-SizeCiaz1,3791,4504,0513,968
Total A: Passenger Cars106,53091,403363,066302,671
B: Utility VehiclesBrezza, Ertiga, S-Cross, XL623,27232,272104,12492,283
C: VansEeco13,04810,05744,81431,840
Total Domestic Passenger Vehicle Sales (PV)142,850133,732512,004426,794
Light Commercial Vehicles (LCV)Super Carry2,8162,76813,6336,824
Total Domestic Sales including LCV (PV+LCV)145,666136,500525,637433,618
Sales to other OEM9,9394,73828,46215,715
Total Domestic Sales (PV+LCV+OEM)155,605141,238554,099449,333
Total Export Sales20,31121,22489,74866,743
Total Sales (Total Domestic + Export)175,916162,462643,847516,076

India’s Most Booked OYOs in Hyderabad located near Business parks 

India’s Most Booked OYOs in Hyderabad located near Business parks 

Global travel technology company, OYO, is spread across 35+ countries with the largest hotel footprint in its headquarters – India. Given the platform’s vast presence across the country, it is easy to spot an OYO almost everywhere. But have you ever wondered which of these takes the top spot as the most popular OYO? Today, in a first, the company unveils its most booked OYOs across Hyderabad. OYO’s data analysis reveals Hyderabad as the third most booked city in India, following Delhi NCR and Bangalore. 

As per the booking analysis, OYO 9405 Hotel Stay Home and Silverkey Executive stays 28060, Gachibowli, tops charts as the platform’s most booked OYO in Hyderabad. These properties rank 7th and 8th respectively on OYO’s Top 10 Most Booked OYOs list across India. Both the properties are located at Gachibowli, a significant IT hub in Hyderabad located approximately 5 km from Hi-Tech City and known to house multiple technology and IT companies. 

With nearly 20 hotels, a majority of OYOs in the top 50 list are located near important transit hubs and key corporate complexes, demonstrating high consumer demand for properties that are centrally located near commercial centers with easy accessibility to transport. This is followed by a high demand for hotels surrounded by nature and lush green views among leisure travellers. 

The high demand for OYOs around key transit hubs can be attributed to the platform’s effort to offer affordable, hygienic stays having important amenities such as air-conditioning, pleasant ambience, fast net connectivity with easy accessibility and flexibility in modification of bookings in case of any last-minute changes.  

India’s Most Booked OYOs in Hyderabad located near Business parks 

India’s Top Ten Most Booked OYOs 

Sr. NoOYO Hotel CityProximity to nearby attractions
1OYO Townhouse 100 Somani TCPuneNear an IT park, highway and entertainment hub
2OYO Townhouse 127 AlphaPuneNear an education hub 
3OYO Townhouse 071 BrookfieldBangaloreNear a commercial hub and residential area
4OYO Townhouse 160 Sector 1 VaishaliGhaziabadNear Vaishali metro station
5OYO Townhouse 024 Sector 47 GurgaonGurgaonNear hospital 
6OYO Flagship 24491 KharadiPuneNear IT park and a national highway 
7OYO 9405 Hotel Stay HomeHyderabadNear IT hub, business park & university
8Silverkey Executive stays 28060, Gachibowli, JV colonyHyderabadNear corporate complex
9OYO 10480 Hotel PMRBangaloreNear IT & Tech hub
10OYO Townhouse 181 Ganeshpeth ColonyNagpurNear parks & ST transport square

Additionally, as per OYO’s data, over 10% of the Top 50 properties maintained an occupancy rate of 100% or above in June 2022, the period for which this ranking has been compiled. Interestingly, nearly 24 of the Top 50 most booked hotels are OYO Townhouses, the platform’s mid-premium stay offering. 

Location-based most booked OYOs 

India’s Most Booked OYOs in Hyderabad located near Business parks 

Another interesting insight is that stays near hospitals have the highest average occupancy rates, suggesting high demand from the patient’s caretakers, visitors and medical staff. High bookings are also visible near key transit hotspots such as railway stations and metros. As air travel bounced back strongly over the past quarter, demand for hotels near the airport also reflected a healthy jump in demand, with Delhi witnessing the highest demand near its Indira Gandhi International Airport in June 2022. Besides Delhi, Jaipur, Mumbai, Lucknow and Surat are the top 5 cities witnessing strong booking uplift in airport proximity hotels in May – June 2022. As per OYO’s data analysis, the Hinjewadi Rajiv Gandhi Infotech Park in Pune emerged as the top commercial hub for highest aggregate OYO bookings. Among transit hubs, OYO witnessed the highest demand at Vaishali Metro Station.

Commenting on OYO’s effort to provide affordable stays for consumers across various segments, Shreerang Godbole, SVP – Product & Chief Service Officer said, “Wherever we go, it’s easy to spot the red OYO logo along the streets of India, be it at leisure destinations, pilgrimage sites, transit hubs or commercial complexes. Such ubiquitous presence across the country allows us to democratize travel for all Indians, whatever their travel intent might be, and opens up vast opportunities for us to provide suitable and quality stays for a wider consumer segment, even at short notice. Our most booked OYO’s list is a good proxy for the location types that see heavy bookings, – be it visiting a loved one at a nearby hospital, staying back at a hotel near your kid’s university, or even heading out on vacations. We hope that with our platform, we continue to serve the requirements of all traveller types who choose to stay with us. To further empower consumers with the power of decision-making around travel, we have also rolled out features such as ‘Pay at hotel’ and flexible booking modifications.”

Inspiring content creators across India, Canon unveils EOS R10 in an experiential

Inspiring-content-creators-

Canon today introduced a one of its kind immersive event series titled #FindYourStory for content creators powered by its latest vlogging heartthrob, the EOS R10. The multi city initiative is aimed at not only familiarizing creators with Canon’s avant-garde vlogging imaging technology but also the skills needed to create exceptional content through specialized workshops by industry mentors.

With the tremendous rise of digital technology and proliferation of social media, content-creation has witnessed a pivotal growth empowered by local storylines. In an endeavor to unlock the potential of creators across India, the event will take place across top 20 towns in the next few months

Appealing to the millennial audience, the first leg of the series was kickstarted at the Museo Camera Centre for Photographic Arts in Gurugram. To curate an exclusive preview for the EOS R10, the invite only event provided customers with a hands-on experience and included riveting workshops by Canon EOS Ambassadors, leading influencers Isa Khan and Niki Mehra and workshops by Sennheiser and Instagram.

Commenting on the activation, Mr. Manabu Yamazaki, President and CEO, Canon India, said “At Canon, we lay great impetus on the growth of photography and videography culture through our innovative product line-up and customer centric market activations. In recent times, we have seen social media democratize the field of content creation across regions and borders. Catering to this segment, we are extremely elated to unveil the latest EOS R10, the perfect companion for content creators and further bring forth initiatives that can help their career grow manifold. Understanding the huge potential that content creator/vlogger segment holds in today’s time, our vision is to empower and upskill the influencer community with focused products and workshops that help them conquer the world of creativity.”

Speaking about the #FindYourStory initiative, he further adds, “This experiential activation is in sync with our larger focus of striking the right chords with the millennial customer group. With the EOS R10, we aim to meet the diverse needs of content creators while serving as an affordable entry-point into Canon’s EOS R system mirrorless technology. Compact and powerful, the Canon EOS R10 is best suited for content creators to #FindTheirStory and narrate it in unique ways through everyday vlogs, reels and shoot in any given environment.”

While the workshops at the event helped enhance product knowledge, it also entailed a number of Instagrammable thematic zones where creators could put their skills to test. Content shot exclusively on the newly unveiled EOS R10 was projected across the event, enticing customers to witness a world of unimaginable creation now possible with the lightweight EOS R10.

Its compact size, built-in popup-style flash and microphone make the EOS R10 the finest choice for vloggers and photo enthusiasts. Whether you are a parent looking to capture precious moments of your child’s milestones; an avid traveller looking for a compact shooting experience; or someone hoping to start your own YouTube channel; the EOS R10 is designed to help create captivating photos and videos with ease.

Superior Image Quality: EOS R10’s new 24.2 megapixel APS-C sensor is designed to provide additional telephoto effect by increasing the focal length by approximately 1.6x while retaining its resolution of 24.2-megapixels, allowing even more creative freedom for post-processing. With a wide normal ISO speed range of 100 to 32 000, the EOS R10 can deliver clean low-noise images even in low-light situations.

High Speed, High Precision: It can perform high-speed continuous shooting at up to 15 fps with the mechanical shutter with AF/AE tracking. The high-speed burst of up to 23fps with the silent electronic shutter* is useful for situations such as concerts, interviews, and wildlife photography. Shutter sound can be activated for electronic shutter if required.

Intelligent Tracking and Recognition: Accurately tracks what matters most. The EOS R10 inherits EOS R3’s ability to differentiate elements within the frame and determine which subject to track. The EOS R10 can recognise people, vehicles and animals – such as cats, dogs and birds – tracking them as they move anywhere in the frame. 

Vlog on the Move: The EOS R10 records uncropped 4K UHD movies processed from rich 6K RGB data for higher image quality with less moiré and minimal colour distortion and noise.

In-Camera Panorama: For the first time in EOS cameras, the Panorama Shot (SCN mode) feature is now available in the EOS R10. Create breathtaking panorama shots in-camera. Capture up to 200 shots at a time and let the camera merge them to form a high-resolution, high-quality panorama shot.

In-Camera Focus Bracketing: By using the Focus Bracketing feature in the EOS R10, users can set a range from 2 – 999 shots to achieve wider depth of field within a scene.

Portable Build: Designed to be lightweight and compact, the EOS R10 uses a sturdy aluminum alloy body for its internal structure to keep the weight at only 429g.

Neha Chauhan and Anuja Sathe join the stellar cast of SonyLIV’s Maharani 2

Anuja-Sathe-join-the-stella

Some stories leave an indelible impression on our minds and keep us yearning for more. One such story is SonyLIV’s Maharani, which had the audience on the edge of their seats with its gripping narrative. Centred around a female lead who navigates the patriarchal hurdles in society to emerge as a formidable political face, the season finale left viewers pining for more. Putting an end to the audience’s wait, the show is back with an exciting season 2 with Neha Chauhan and Anuja Sathe joining ensemble cast.

Neha Chauhan

Neha Chauhan will be seen playing the role of Kalpana Kaul – a suave and ambitious woman, running her own political consultancy firm called I-ACT.  Talking about her role, Neha said, “I have been a big fan of the show since the first season, so it feels great to join such a stellar cast and work with the wonderful Subhash Kapoor Sir. My character will take things up a notch and catalyse plot twists that will unfold this season. I have never done anything like this before and am excited to see the audience’s reaction.”

Stepping into the shoes of a political candidate, Anuja Sathe portrays Kirti Singh, who becomes Bheema Bharti’s (Sohum Shah) confidante. Commenting on her role, she said, “I have always been very lucky when it comes to roles. Keeping the trend alive, the audience will see me in a new avatar in this show. Kirti is totally opposite to how I am in real life, so it was an exciting and fulfilling experience for me as an actor. I had to be convincing while portraying the various shades of my character. The entire cast and crew have been very supportive, and I had a great time working with all of them.”

Anuja-Sathe-join-the-stella

Maharani 2 is directed by Ravindra Gautam, with Subhash Kapoor and Nandan Singh serving as showrunners and writers of the show. Headlined by Huma Qureshi, the show also features, Sohum Shah, Amit Sial, Vineet Kumar, Inaamulhaq, Dibyendu Bhattacharya, Kani Kasturi, Pramod Pathak and Vineet Kumar in prominent roles.

Samsung to Host Galaxy Unpacked on August 10; Get Ready to Unfold Your World

samsung

Telugu super news.com,Hyderabad, July29th,2022: Samsung Electronics announced that it will unveil the next generation of its foldable smartphones on August 10, 2022. Samsung has been pushing boundaries, defying conventions and opening doors to new experiences. Meangingful innovations go beyond the technical and provide a platfrom upon which our everyday lives become richer and more versatile.

samsung

Join us to unlock new experiences that transform our lives for the better and open us up to greater possibilities than ever before. Galaxy Unpacked will take place on August 10, 2022 and will be livestreamed on Samsung Newsroom India starting 6:30pm IST. Stay tuned to Samsung Newsroom for regular updates ahead of the event.

Dr. Reddy’s Q1 FY23 Financial Results

Dr.reddys

Telugusupernews.com,Hyderabad, India, July 29, 2022: Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY |NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2022. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS).

Dr.reddys

Commenting on the results, Co-Chairman & MD, G V Prasad said “Our underlying business revenues adjusted for
covid products contribution during last year have grown well. The profits were aided by a few non-recurring
incomes, offsetting the near term headwinds. We continue to improve the health of our core businesses through
productivity improvement and robust product pipelines”.
Revenues
Gross Margin

SG&A Expenses

R&D Expenses

EBITDA

Profit before Tax

Profit after Tax

Rs. 5,215 Cr
[Up: 6% YoY; Down: 4% QoQ]
49.9%
[Q1 FY22: 52.2%; Q4 FY22: 52.9%]
Rs. 1,549 Cr
[Up: 3% YoY; Down: 1% QoQ]
Rs. 433 Cr
[8.3% of Revenues]
Rs. 1,779 Cr
[34.1% of Revenues]
Rs. 1,466 Cr
[Up: 97% YoY; Up: 490% QoQ]
Rs. 1,188 Cr
[Up: 108% YoY; Up: 1,257% QoQ]

2
All amounts in millions, except EPS All US dollar amounts based on convenience translation rate of I USD = Rs. 79.02

Dr. Reddy’s Laboratories Limited and Subsidiaries

Consolidated Income Statement
Particulars Q1 FY23 Q1 FY22 YoY
Gr %

Q4 FY22 QoQ
Gr% ($) (Rs.) ($) (Rs.) ($) (Rs.)

Revenues 660 52,154 623 49,19

4 6 688 54,36
8 (4)
Cost of Revenues 331 26,148 297 23,495 11 324 25,625 2
Gross Profit 329 26,006 325 25,69

9 1 364 28,74
3 (10)


Operating Expenses                
Selling, General & Administrative
expenses 196 15,493 190 15,045 3 198 15,674 (1)
Research and Development
expenses 55 4,325 57 4,534 (5) 55 4,326 (0)
Impairment of non-current assets – – – – 95 7,515 (100)
Other operating income (76) (6,024) (6) (487) 1,137 (4) (291) 1,970
Results from operating activities 155 12,212 84 6,607 85 19 1,519 704
Net finance income (30) (2,349) (8) (652) 260 (11) (859) 173
Share of profit of equity accounted
investees (1) (94) (2) (166) (43) (1) (105) (10)
Profit before income tax 185 14,655 94 7,425 97 31 2,483 490
Income tax expense 35 2,779 22 1,717 62 20 1,608 73
Profit for the period 150 11,876 72 5,708 108 11 875 1,257
Diluted Earnings Per Share (EPS) 0.90 71.40 0.43 34.34 109 0.07 5.26 1,261

Dr.reddys

As % to revenues Q1 FY23 Q1 FY22 Q4 FY22
Gross Profit 49.9 52.2 52.9
SG&A 29.7 30.6 28.8
R&D 8.3 9.2 8.0
EBITDA 34.1 20.7 23.9
PBT 28.1 15.1 4.6
PAT 22.8 11.6 1.6

EBITDA Computation

Particulars Q1 FY23 Q1 FY22 Q4 FY22
($) (Rs.) ($) (Rs.) ($) (Rs.)
Profit before Income Tax 185 14,655 94 7,425 31 2,483
Interest (income) / expense (net)* 1 84 (2) (142) 0 24
Depreciation 26 2,050 25 1,973 26 2,039
Amortization 13 1,000 12 932 12 920
Impairment – – – – 95 7,515
EBITDA 225 17,789 129 10,188 164 12,98
0

3

Dr.reddys
  • Includes income from Investments
    All amounts in millions, except EPS All US dollar amounts based on convenience translation rate of I USD = Rs. 79.02

Key Balance Sheet Items

Particulars

As on 30 th Jun
2022

As on 31 st Mar
2022

As on 30 th Jun
2021
($) (Rs.) ($) (Rs.) ($) (Rs.)

Cash and cash equivalents and other
investments 449 35,467 608 48,033 435 34,356
Trade receivables 927 73,274 846 66,818 774 61,148
Inventories 656 51,810 644 50,884 643 50,771
Property, plant and equipment 808 63,826 787 62,169 742 58,636
Goodwill and Other Intangible assets 458 36,213 401 31,664 503 39,746
Loans and borrowings (current & non-current) 312 24,666 428 33,845 422 33,373
Trade payables 317 25,052 324 25,572 362 28,607
Equity 2,531 2,00,039 2,411 1,90,52

7 2,254 1,78,11
4

Dr.reddys

Revenue Mix by Segment
Segment Q1 FY23 Q1 FY22 YoY
Gr %

Q4 FY22 QoQ
Gr % (Rs.) (Rs.) (Rs.)
Global Generics 44,324 41,113 8 46,118 (4)
North America 17,815 17,390 2 19,971 (11)
Europe 4,141 3,994 4 4,444 (7)
India 13,339 10,600 26 9,689 38
Emerging Markets 9,028 9,129 (1) 12,013 (25)
Pharmaceutical Services and Active
Ingredients (PSAI) 7,090 7,540 (6) 7,557 (6)
Others 740 541 37 693 7
Total 52,154 49,194 6 54,368 (4)

34%

8%

26%
17%
14%
1%
Q1 FY23 Sales Mix

North America
Europe
India
Emerging Markets
PSAI
Others

4

Revenue Analysis
Global Generics (GG)
Revenues from GG segment at Rs. 44.3 billion:
 Year-on-year growth of 8% was driven by new product launches across most of our businesses and
divestment of a few non-core brands in India, partly offset by price erosion in our generic markets,
and higher base due to covid product sales in previous year.
 Sequential decline of 4% was due to sales decline in North America (incremental competition on key
products and price erosion) and Emerging Markets (normalization of channel inventory in Russia).
This was partly offset by new product launches.
North America
Revenues from North America at Rs. 17.8 billion:
 Year-on-year growth of 2%, driven by launch of new products and favorable forex rates, which was
offset by price erosion in some of our key molecules.
 Sequential decline of 11% was primarily on account of price erosion and decline in volumes for few
products due to incremental competition.
 During this quarter, we launched 7 new products. This includes launch of Ketorolac, OTC Nicotine
Lozenges Original, Methylprednisolone Sodium Succinate, Pemetrexed Injection, Posaconazole Tabs
and Sorafenib in the US and Pemetrexed Inj. in Canada.
 We filed three ANDAs during the quarter. As of 30 th June 2022, cumulatively 86 generic filings are
pending for approval with the USFDA (83 ANDAs and 3 NDAs under 505(b)(2) route). Out of these
86 pending filings, 44 are Para IVs and we believe 24 have ‘First to File’ status.
Europe
Revenues from Europe at Rs. 4.1 billion:
 Year-on-year growth of 4%, driven by launch of new products and scale up of base business, which
was partly offset by price erosion in some molecules and adverse forex rates during the quarter.
 Sequential decline of 7% was primarily on account of price erosion and adverse forex rates, which
was partly offset by volume traction in base business.
India
Revenues from India at Rs. 13.3 billion:
 Year-on-year growth of 26% was driven by divestment of a few non-core brands, revenue
contribution from the products acquired / in-licensed from Novartis, growth in base business and
new products contribution. The growth was partially offset due to covid product sales in Q1 FY22
which was not there in the current quarter.

5
 Sequential growth of 38% was primarily driven by divestment of a few non-core brands, revenue
contribution from the products acquired / in-licensed from Novartis, new products contribution
and growth in base business.
 We launched five new products during the quarter.
Emerging Markets
Revenues from Emerging Markets at Rs. 9.0 billion. Year-on-year decline of 1% and sequential decline of
25%:
 Revenues for Russia at Rs. 3.2 billion. Year-on-year decline of 9% is primarily due to channel
inventory normalization post stocking up in Q4 FY22, which was partly offset with launch of new
products. Sequential decline of 53% was due to higher base in Q4 FY22 from brand divestment
income and channel inventory normalization in the current quarter.
 Revenues from other CIS countries and Romania at Rs. 1.9 billion. Year-on-year growth of 33%
driven by volume traction in base business, favorable price benefits in some of our products and
launch of new products. Sequential decline of 16% was primarily on account of reduction in
volumes.
 Revenues from Rest of World (RoW) territories at Rs. 3.9 billion. Year-on-year decline of 6%
primarily on account of higher base in Q1 FY22 due to covid product sales and price decline in
current quarter, partly offset by new product launches. Sequential growth of 36% was largely
attributable to volume traction in our base business, price benefits in some of our markets and
launch of new products.
Pharmaceutical Services and Active Ingredients (PSAI)
Revenues from PSAI at Rs. 7.1 billion. Year-on-year and sequential decline of 6% each.
 Year-on-year decline was primarily on account of higher base in Q1 FY22 with covid product sales,
partly offset by new products launched and favorable forex rates.
 Sequential decline was primarily due to lower volumes of base business, partly offset by new
product launches.

6

Income Statement Highlights:
 Gross profit margin at 49.9%:

Dr.reddys
  • Decreased by ~230 bps over previous year and by ~300 bps sequentially, primarily on account
    of higher commodity prices, adverse leverage on manufacturing overheads, price erosion and
    forex related impact, which was partially benefited from brand divestment income.
  • Gross profit margin for GG and PSAI business segments are at 55.0% and 15.7% respectively.
     Selling, general & administrative (SG&A) expenses at Rs. 15.5 billion, increased by 3% on a year-
    on-year basis and declined by 1% sequentially. Year-on-year increase was primarily attributable to
    investments being done towards marketing of some of our key brands, investments in digitalization
    and annual increments, which was partially offset with lower legal and professional expenses. On
    sequential basis, the expenses have been largely flat.
     Research & development (R&D) expenses at Rs. 4.3 billion. As % to revenues – Q1 FY23: 8.3% | Q4
    FY22: 8.0% | Q1 FY22: 9.2%. Our focus continues on building a global pipeline of products across our
    markets.
     Other operating income at Rs. 6.0 billion compared to Rs. 0.5 billion in Q1 FY22. The increase was
    mainly on account of recognition of income from settlement agreement, with Indivior Inc., Indivior UK
    Limited and Aquestive Therapeutics, Inc., resolving all claims between the parties relating to the
    generic buprenorphine and naloxone sublingual film.
     Net Finance income at Rs. 2.3 billion compared to Rs. 0.7 billion in Q1 FY22. The increase was
    primarily on account of foreign exchange gains due to favorable ruble rates.
     Profit before Tax at Rs. 14.7 billion, increased by 97% year-on-year and increased by 490%
    sequentially.
     Profit after Tax at Rs. 11.9 billion. The effective tax rate is 19.0% for the quarter.
     Diluted earnings per share is at Rs. 71.40.
    Other Highlights:
     EBITDA is at Rs. 17.8 billion and the EBITDA margin is 34.1%.
     Capital expenditure is at Rs. 3.3 billion.
     Free cash-flow is a net outflow of Rs. 2.3 billion.
     Net cash surplus for the company is at Rs. 12.8 billion as on June 30, 2022. Consequently, net debt to
    equity ratio is (0.06).

7
Earnings Call Details (06:30 pm IST, 09:00 am EDT, July 28, 2022)
The management of the Company will host an earnings call to discuss the Company’s financial
performance and answer any questions from the participants.
Conference Joining Information
Option 1: Express Join with DiamondPass™
Pre-register with the below link and join without waiting for the operator.
https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=3962534&linkSecurityString=119134f0e6
Option 2: Join through below Dial-In Numbers
Universal Access Number: +91 22 6280 1219
+91 22 7115 8120

International Toll Free
Number:

USA: 1 866 746 2133
UK: 0 808 101 1573
Singapore: 800 101 2045
Hong Kong: 800 964 448

No password/pin number is necessary to dial in to any of the above numbers. The operator will
provide instructions on asking questions before and during the call.
Play Back: The play back will be available after the earnings call, till August 3 rd , 2022. For play
back dial in phone No: +91 22 7194 5757 | +91 22 6663 5757, and Playback Code is 96436.
Transcript: Transcript of the Earnings call will be available on the Company’s

Freedom Oil | దేశంలోనే నంబర్ వన్ బ్రాండ్ గా ఫ్రీడమ్ రిఫైన్డ్ సన్‌ఫ్లవర్ ఆయిల్

best sunflower oil in india

తెలుగు సూపర్ న్యూస్,హైదరాబాద్ ,జూన్ 24,2022జెమినీ ఎడిబుల్స్ అండ్ ఫ్యాట్స్ ఇండియా లిమిటెడ్ ఫ్లాగ్‌షిప్ బ్రాండ్ ఫ్రీడమ్ రిఫైన్డ్ సన్‌ఫ్లవర్ ఆయిల్ ఇండియాలో సన్‌ఫ్లవర్ ఆయిల్ సెగ్మెంట్‌లో ఈ ఏడాది వాల్యూమ్ సేల్స్ ప్రకారం నంబర్ వన్ బ్రాండ్‌గా ర్యాంక్ సాధించింది. ఈ సందర్భంగా జెమినీ ఎడిబుల్స్ అండ్ ఫ్యాట్స్ ఇండియా లిమిటెడ్ మేనేజింగ్ డైరెక్టర్ ప్రదీప్ చౌదరి మాట్లాడుతూ సన్‌ఫ్లవర్ ఆయిల్ కేటగిరీలో 20.5% విలువతో ‘ఫ్రీడమ్’ భారతదేశంలో నంబర్ వన్ బ్రాండ్‌గా అవతరించినందుకు మేము సంతోషిస్తున్నాం” ఇది మా వినియోగదారు-కేంద్రీకృత విధానం, పటిష్టమైన పంపిణీ నెట్‌వర్క్, నాణ్యతపై దృష్టి పెట్టడం ఫలితంగా మా బ్రాండ్ ఈ విజయం సొంతం చేసుకుంది. రాబోయే కొద్ది సంవత్సరాలలో సన్‌ఫ్లవర్ ఆయిల్ వినియోగం ఎక్కువగా ఉన్న తమిళనాడు, కేరళలో ప్రారంభించాలని మేము భావిస్తున్నామని ఆయన పేర్కొన్నారు.

best sunflower oil in india

‘భారతదేశంలో ముడి సన్‌ఫ్లవర్ ఆయిల్ అత్యధిక దిగుమతిదారు’ విభాగంలో ప్లాటినం అవార్డును కైవసం చేసుకుంది. 2018లో The Globoil India ‘Emerging Brand’ అవార్డు ‘ఫ్రీడమ్’ బ్రాండ్‌కు దక్కింది. ఇండియా టుడే ‘ఇస్పోస్ అర్బన్ కన్స్యూమర్ సెంటిమెంట్ సర్వే 2020’ ప్రకారం ‘ఫ్రీడమ్’ బ్రాండ్ భారతదేశంలోని టాప్ ఫైవ్ వంట నూనె బ్రాండ్‌లలో ఒకటిగా నిలిచింది.

1 42 43 44